Risk of rhabdomyolysis with concomitant use of statins and SGLT2 inhibitors: A population‐based cohort study
The authors declare no conflicts of interest. The data that support the findings of this study are available from TriNetX. Restrictions apply to the availability of these data, which were used under license for this study. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Authors
- Hesham Sheashaa
- Milagros Pereyra (ORCID: https://orcid.org/0000-0003-4695-8436)
- Mahshad Razaghi (ORCID: https://orcid.org/0000-0002-0756-3004)
- Isabel G. Scalia (ORCID: https://orcid.org/0000-0002-6459-9767)
- Ramzi Ibrahim (ORCID: https://orcid.org/0000-0003-0124-9513)
- Juan Farina (ORCID: https://orcid.org/0000-0002-5824-8485)
- Fatmaelzahraa E. Abdelfattah (ORCID: https://orcid.org/0009-0008-0758-1086)
- Mohammed Tiseer Abbas
- Steven J. Lester
- Hana Mousa
- Reza Arsanjani
- Ahmed K. Mahmoud
- Chadi Ayoub
- Kamal Awad
Institutions
- Boston Medical Center (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Journal of Internal Medicine
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1111/joim.70062
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00